RevMed Q4 net loss widens to USD 364.9 million (87.5%)

Revolution Medicines (RVMD) reported a Q4 net loss of USD 364.9 million and a FY 2025 net loss of USD 1.1 billion. Q4 R&D expenses were USD 294.9 million (+56.8%) and G&A expenses were USD 66.7 million (+136.5%). For FY 2025, R&D expenses were USD 987.3 million (+66.7%) and G&A expenses were USD 195.0 million (+100.4%). Cash, cash equivalents and marketable securities totaled USD 2.0 billion at December 31, 2025, including a USD 250.0 million royalty monetization tranche received in June 2025, with an additional USD 1.8 billion in future committed capital under the Royalty Pharma arrangement. The company said global enrollment is complete in RASolute 302, its Phase 3 trial of daraxonrasib monotherapy in second-line metastatic pancreatic ductal adenocarcinoma (PDAC), with a readout expected in H1 2026. Revolution Medicines also highlighted initiation of RASolute 305, a Phase 3 trial of zoldonrasib in first-line metastatic PDAC harboring a RAS G12D mutation, and said it expects to substantially complete enrollment this year in RASolve 301, a Phase 3 trial of daraxonrasib in previously treated non-small cell lung cancer (NSCLC). It also noted FDA Breakthrough Therapy designation for zoldonrasib in previously treated RAS G12D NSCLC, and said it plans to initiate RASolve 308, a Phase 3 trial of zoldonrasib in first-line metastatic RAS G12D NSCLC, in H1 2026. For 2026, the company guided for GAAP operating expenses of USD 1.6 billion to USD 1.7 billion, including estimated non-cash stock-based compensation expense of USD 180.0 million to USD 200.0 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602251602PRIMZONEFULLFEED9661375) on February 25, 2026, and is solely responsible for the information contained therein.